Africa News Line Saturday, 12.03.2022, 11:31 AM
Welcome Guest | RSS
Site menu

Main » 2021 » December » 12

Organizations can now automate legal entity data health checks to identify, report and address discrepancies in real time

NEW YORK -Saturday 11 December 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Diligent, the global leader in SaaS governance, risk and compliance (GRC), today announces the release of its company health check capability, powered by Dun & Bradstreet, within Diligent’s Entity & Subsidiary Management solution.

Diligent provides organizations with a powerful solution to automate core processes of entity management, including document creation, entity lifecycle management, reminders and alerts. Through the partnership, organizations can now tap into Dun & Bradstreet’s Data Cloud, the world’s most comprehensive index of business-decisioning data and analytics, to verify if their entity data matches what has been filed across global jurisdictions. This level of verification improves a company’s data quality, flags poten ... Read more »

Views: 49 | Added by: africa-live | Date: 12.12.2021 | Comments (0)

Brightcove customers can experience robust results, including a 225% and 226% ROI in less than six months, independent studies show

BOSTON-Sunday 5 December 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Brightcove Inc. (Nasdaq: BCOV), the global leader in video for business, released findings that enterprises and media organizations can generate 225% and 226% ROI respectively with Brightcove and see a full return on the initial investment in less than six months. The commissioned Total Economic Impact™ (TEI) studies conducted by Forrester Consulting examined cost savings and business benefits with Brightcove solutions for enterprise and media organizations.

Forrester Consulting interviewed decision-makers at multiple enterprise and media organizations with experience using Brightcove. Respondents came from organizations headquartered in the US and EMEA, all with multi-billion dollars of annual revenues. The enterprise interviewees represented industries includi ... Read more »

Views: 66 | Added by: africa-live | Date: 12.12.2021 | Comments (0)

Defense, Intelligence, and Commercial Organizations Can Now Seamlessly Access Basemaps and Visualize Data via Orbital Insight GO


REDLANDS, Calif.-Saturday 4 December 2021 [ AETOS Wire ]

(BUSINESS WIRE) -- Orbital Insight's fusion of multisensor geospatial data and state-of-the-art algorithms has been helping customers address critical concerns for years—from determining the flow of container ship traffic amid unprecedented supply chain delays to visualizing dynamic intelligence and defense-related threats and anomalies across the globe. With the adoption of Esri's ArcGIS Platform, Orbital Insight is making it easier for its users to integrate with ArcGIS and analyze their data.

Customers of Esri, the world leader in location intelligence, who also use Orbital Insight GO can now seamlessly work between both systems, making it easier to meet spatial challenges with Esri basemap visualizations directly within the Orbital Insight GO platform ... Read more »

Views: 65 | Added by: africa-live | Date: 12.12.2021 | Comments (0)

GALWAY, Ireland -Friday 10 December 2021 [ AETOS Wire ]

GALWAY, Ireland--(BUSINESS WIRE)-- Following months of collaborative development work, Aerogen® (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) have announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia™ utilizing Aerogen’s proprietary vibrating mesh aerosol drug delivery technology.

The aerosolised vaccine is directly inhaled via a cup dispenser into the patient’s airway. This route mimics the natural infection pathway of the respiratory virus COVID-19 and may create additional benefits through generating mucosal immunity.

The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia™ has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.1

Inoculation by the inhaled ... Read more »

Views: 50 | Added by: africa-live | Date: 12.12.2021 | Comments (0)

ST. GALLEN, Switzerland -Friday 10 December 2021 [ AETOS Wire ]

 

Hervé Gisserot will join Vifor Pharma as Chief Commercial Officer on 17 January 2022
Responsibilities of Sales, Marketing and Market Access to be streamlined under Chief Commercial Officer role to prioritize commercial execution
(BUSINESS WIRE)-- Regulatory News:

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Vifor Pharma Group today announced the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Vifor Pharma Executive Committee as of 17 January 2022.

Hervé Gisserot, a French citizen, is an experienced industry executive and has a proven track record of building and leading organizations across the U.S., Europe and Asia Pacific with extensive launch and market access experiences. He joins from GlaxoSmithKline where he served in multiple Senior Vice President roles in the last 13 years. He is a graduate of the Institute of Political Science ... Read more »

Views: 43 | Added by: africa-live | Date: 12.12.2021 | Comments (0)

 IMPACT allows users to invest according to their values and create the world they want to see

 

GREENWICH, Conn.-Friday 10 December 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Interactive Brokers Group (Nasdaq: IBKR), a global brokerage firm, today introduced IMPACT to investors worldwide. IMPACT is a patent pending mobile trading application designed to help investors easily align their portfolios with their values and help shape the future they wish to see. Expanding upon our Environmental, Social and Governance (ESG) trading initiatives, IMPACT by Interactive Brokers features a simple and intuitive app design that streamlines the sustainable investing process for any investor. Following the launch of IMPACT to U.S. investors, the global launch comes at a time when ESG considerations have become increasingly important to investors on a global scale. The Global Impact Investor Network estimates the total size of the market at USD 715 billion managed by ... Read more »

Views: 50 | Added by: africa-live | Date: 12.12.2021

BEERSE, Belgium -Saturday 11 December 2021 [ AETOS Wire ]

 For EU Trade and Medical Media Only. Not to Be Distributed to UK and Benelux Based Media

Conditional Marketing Authorisation is based on results from the Phase 1 CHRYSALIS study evaluating amivantamab as a monotherapy in patients after previous treatment with platinum-based therapy1,2,3

(BUSINESS WIRE)--  

Janssen EMEA Receives Conditional Marketing Authorisation for RYBREVANT® ▼ (amivantamab), the First Treatment Approved for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy

The Janssen Pharmaceutical Companies of Johnson & Johnson announced Conditional Marketing Authorisation (CMA) of RYBREVANT® ▼ (amivantamab) for the treatment of adult patients with advanced NSCLC with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations, after failure of platinum-ba ... Read more »

Views: 58 | Added by: africa-live | Date: 12.12.2021 | Comments (0)

ST. GALLEN, Switzerland & UNIONDALE, N.Y. -Friday 10 December 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced results from the exploratory phase-II GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC). However, Angion and Vifor Pharma continue to review the data, based on the signal demonstrated in the clinically-relevant MAKE90 secondary endpoint.

The GUARD trial was designed as a signal-finding trial with a primary objective determining the feasibility of adv ... Read more »

Views: 53 | Added by: africa-live | Date: 12.12.2021 | Comments (0)

Search

Entries archive

Calendar